Proposed FDA Rule Could Limit Pharmacy Compounding - Pharmacy Times
Proposed FDA rule could restrict pharmacy compounding, affecting availability of compounded medications, especially controlled substances.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Compounding pharmacies, independent pharmacies, retail chains, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period open; final rule expected within 12-18 months. Begin assessment now.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA proposes new limits on compounding, potentially restricting formulations and quantities of compounded drugs, including controlled substances.
Who it affects
Compounding pharmacies, independent pharmacies, retail chains, long-term-care pharmacies
What you must do
Review current compounding practices and prepare to adjust operations to comply with proposed limits.
Deadline
Comment period open; final rule expected within 12-18 months. Begin assessment now.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order